Takeda Pharmaceutical (TAK) Competitors

Sanofi (NASDAQ:SNY) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Do analysts recommend SNY or TAK?

Sanofi currently has a consensus price target of $61.50, indicating a potential upside of 26.75%. Given Sanofi's stronger consensus rating and higher probable upside, analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanofi	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.11
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher valuation & earnings, SNY or TAK?

Sanofi has higher earnings, but lower revenue than Takeda Pharmaceutical. Sanofi is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanofi	$44.46B	2.68	$6.02B	$2.80	17.33
Takeda Pharmaceutical	$4.58T	0.01	$712.33M	$0.22	66.89

Is SNY or TAK more profitable?

Sanofi has a net margin of 14.56% compared to Takeda Pharmaceutical's net margin of 2.36%. Sanofi's return on equity of 17.15% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanofi	14.56%	17.15%	9.80%
Takeda Pharmaceutical	2.36%	10.64%	5.14%

Do institutionals and insiders hold more shares of SNY or TAK?

14.0% of Sanofi shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.0% of Sanofi shares are held by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Is SNY or TAK a better dividend stock?

Sanofi pays an annual dividend of $1.60 per share and has a dividend yield of 3.3%. Takeda Pharmaceutical pays an annual dividend of $0.55 per share and has a dividend yield of 3.7%. Sanofi pays out 57.1% of its earnings in the form of a dividend. Takeda Pharmaceutical pays out 250.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Which has more risk & volatility, SNY or TAK?

Sanofi has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.

Does the media prefer SNY or TAK?

In the previous week, Sanofi had 34 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 38 mentions for Sanofi and 4 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.29 beat Sanofi's score of 0.77 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanofi	14 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sanofi beats Takeda Pharmaceutical on 15 of the 19 factors compared between the two stocks.